IL17RA Blocking Antibody: Effective Solutions for Immune Disorders

Alpha Lifetech Incorporation proudly presents our innovative IL17RA blocking antibody, a groundbreaking solution designed for cutting-edge research in immunology. This high-quality antibody specifically targets the IL-17 receptor A (IL17RA), pivotal in numerous inflammatory diseases and autoimmune disorders. By blocking this receptor, researchers can effectively study the role of IL-17 signaling pathways in various pathological conditions, Our IL17RA blocking antibody is produced using advanced technologies and rigorous quality control, ensuring high specificity, sensitivity, and reproducibility in experiments. It is ideal for applications such as Western blotting, ELISA, and immunohistochemistry, making it a versatile tool for laboratories dedicated to exploring therapeutic strategies for conditions like psoriasis, rheumatoid arthritis, and beyond, With a commitment to scientific advancement, Alpha Lifetech Incorporation aims to support researchers in their quest for innovative solutions through high-quality reagents. Elevate your research capabilities with our IL17RA blocking antibody and unlock new possibilities in your studies

Hot Selling Product

ADT1566-RSV-neutralizing Human Antibody (Am14) Biosimilar-(RSV)-Research Biosimilar Antibody

ADT1006-Abelacimab Biosimilar (F11)-Research Biosimilar Antibody

ADT1743-Human Anti-PD-1xCTLA-4 Bispecific Antibody

ADT1747-Human Anti-EGFRxMET Bispecific Antibody

ADT1749-Human Anti-CD3ExCD20 Bispecific Antibody

ADT1754-Human Anti-CD3xClaudin18.2 Bispecific Antibody

Best Options For IL17RA blocking antibody Your Trusted OEM Partner Products

At Alpha Lifetech Inc., we pride ourselves on being a leading provider of high-quality biotechnology products, specializing in the development of cutting-edge reagents including IL17RA blocking antibodies. Founded by a team of seasoned scientists with deep expertise in membrane Protein production and monoclonal development, we understand the critical role that innovative solutions play in advancing research and therapies worldwide. Our IL17RA blocking antibodies are meticulously designed to target and inhibit the interleukin-17 receptor A, a critical component in various inflammatory and autoimmune disorders. With nearly 10,000 high-quality reagents, we deliver reliable products that empower researchers and clinicians to achieve their goals. Partnering with us not only gives you access to superior products but also to a dedicated team that is committed to your success. As a trusted OEM partner, we offer tailored solutions to meet your specific requirements, ensuring that you receive the best options for your research endeavors. We invite global procurement professionals to explore our extensive catalog and discover how Alpha Lifetech can support your projects with unparalleled quality and expertise. Whether you are in academia or the pharmaceutical industry, our products are designed to help you make significant advancements in your work. Choose Alpha Lifetech as your trusted partner in innovation and excellence in the field of biotechnology.

Best Options For IL17RA Blocking Antibody Your Trusted OEM Partner Products

Product Name	Host Species	Isotype	Application	Concentration (mg/ml)
IL17RA Antibody Clone A	Mouse	IgG1	Western Blot, ELISA	1.0
IL17RA Blocking Antibody B	Rabbit	IgG	Neutralization, Flow Cytometry	0.5
IL17RA Inhibitor Antibody C	Goat	IgG	Immunohistochemistry, ELISA	2.0
IL17RA Antibody Clone D	Rat	IgG2a	Western Blot, Immunoprecipitation	1.5

IL17RA Blocking Antibody Efficacy Analysis

The IL17RA blocking antibody has shown a significant increase in efficacy over a six-week period, as demonstrated in the chart above. The data indicates a steady rise in effectiveness, starting at 45% in Week 1 and achieving an impressive 90% by Week 6. This upward trend suggests that the antibody is not only effective but may also improve over time with continued administration. The results highlight the potential of IL17RA blocking antibodies in therapeutic applications, particularly for conditions associated with IL-17 signaling pathways. Continuous monitoring and analysis will be essential to further explore the mechanisms behind its efficacy and to optimize treatment protocols for various patient populations. As research progresses, this data provides a foundational understanding for future clinical investigations and applications in targeted therapies.